Skip to Main Content
Table 3.

Prevalence of HPV in HNSCCs by cancer site and geographic location

No. studiesNo. casesOverall HPV prevalence (95% CI)HPV16 prevalence (95% CI)
Oral cavity     
    Europe 15 744 16.0 (13.4-18.8) 10.8 (8.6-13.2) 
    North America 577 16.1 (13.2-19.4) 10.1 (7.7-12.8) 
    Asia 13 1,133 33.0 (30.3-35.8) 22.3 (20.3-25.2) 
    Other* 188 18.1 (12.9-24.3) 14.9 (10.1-20.8) 
Oropharynx     
    Europe 17 529 28.2 (24.4-32.2) 23.8 (20.2-27.7) 
    North America 285 47.0 (41.1-53.0) 42.1 (36.3-48.1) 
    Asia 54 46.3 (32.6-60.4) 35.2 (22.7-49.4) 
    Other* 101 36.6 (27.3-46.8) 33.7 (24.6-43.8) 
Larynx     
    Europe 19 799 21.3 (18.5-24.3) 13.8 (11.5-16.4) 
    North America 297 13.8 (10.1-18.3) 10.1 (7.0-14.1) 
    Asia 306 38.2 (32.8-43.9) 26.5 (21.6-31.8) 
    Other* 33 48.5 (30.8-66.5) 45.5 (28.1-63.6) 
No. studiesNo. casesOverall HPV prevalence (95% CI)HPV16 prevalence (95% CI)
Oral cavity     
    Europe 15 744 16.0 (13.4-18.8) 10.8 (8.6-13.2) 
    North America 577 16.1 (13.2-19.4) 10.1 (7.7-12.8) 
    Asia 13 1,133 33.0 (30.3-35.8) 22.3 (20.3-25.2) 
    Other* 188 18.1 (12.9-24.3) 14.9 (10.1-20.8) 
Oropharynx     
    Europe 17 529 28.2 (24.4-32.2) 23.8 (20.2-27.7) 
    North America 285 47.0 (41.1-53.0) 42.1 (36.3-48.1) 
    Asia 54 46.3 (32.6-60.4) 35.2 (22.7-49.4) 
    Other* 101 36.6 (27.3-46.8) 33.7 (24.6-43.8) 
Larynx     
    Europe 19 799 21.3 (18.5-24.3) 13.8 (11.5-16.4) 
    North America 297 13.8 (10.1-18.3) 10.1 (7.0-14.1) 
    Asia 306 38.2 (32.8-43.9) 26.5 (21.6-31.8) 
    Other* 33 48.5 (30.8-66.5) 45.5 (28.1-63.6) 
*

Includes Central and South America, Australia, and Africa.

Larynx includes cases of the hypopharynx.

Close Modal

or Create an Account

Close Modal
Close Modal